These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 30789355)
1. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression. Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355 [TBL] [Abstract][Full Text] [Related]
2. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression. Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947 [TBL] [Abstract][Full Text] [Related]
3. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma]. Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256 [No Abstract] [Full Text] [Related]
4. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970 [TBL] [Abstract][Full Text] [Related]
5. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters. Hashmi AA; Mudassir G; Hashmi RN; Irfan M; Asif H; Khan EY; Abu Bakar SM; Faridi N Asian Pac J Cancer Prev; 2019 Sep; 20(9):2601-2606. PubMed ID: 31554352 [TBL] [Abstract][Full Text] [Related]
6. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172 [TBL] [Abstract][Full Text] [Related]
7. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223 [TBL] [Abstract][Full Text] [Related]
8. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935 [TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer]. Jin W; Wang LQ; Liu Y; Liu AJ Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020 [No Abstract] [Full Text] [Related]